Early initiation of enzyme replacement therapy for the mucopolysaccharidoses
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The mucopolysaccharidoses (MPS), a group of rare genetic disorders caused by defects in glycosaminoglycan (GAG) catabolism, are progressive, multi-systemic diseases with a high burden of morbidity. Enzyme replacement therapy (ERT) is available for MPS I, II, and VI, and may improve walking ability, endurance, and pulmonary function as evidenced by data from pivotal trials and extension studies. Despite these demonstrable benefits, cardiac valve disease, joint disease, and skeletal disease, all of which cause significant morbidity, do not generally improve with ERT if pathological changes are already established. Airway disease improves, but usually does not normalize. These limitations can be well understood by considering the varied functions of GAG in the body. Disruption of GAG catabolism has far-reaching effects due to the triggering of secondary pathogenic cascades. It appears that many of the consequences of these secondary pathogenic events, while they may improve on treatment, cannot be fully corrected even with long-term exposure to enzyme, thereby supporting the treatment of patients with MPS before the onset of clinical disease. This review examines the data from clinical trials and other studies in human patients to explore the limits of ERT as currently used, then discusses the pathophysiology, fetal tissue studies, animal studies, and sibling reports to explore the question of how early to treat an MPS patient with a firm diagnosis. The review is followed by an expert opinion on the rationale for and the benefits of early treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Taylor, K. R., & Gallo, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.05-4682rev · Cited by 639 · cited 1×
“Their storage appears to lead to the perturbation of cellular, tissue, and organ homeostasis through secondary pathogenic cascades [40,41,44–47].”
BackgroundNeufeld, E. F., & Fratantoni, J. C. (1970) · Science · doi:10.1126/science.169.3941.141 · Cited by 215 · cited 1×
“Historically itwas believed that the primary storage of GAG and their deposition in tissues was solely responsible for the signs and symptoms associated with theMPS [39], but recent research suggests a more complex picture [40].”
Background
Cited by
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome
Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106596 · Cited by 171
In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease
Bose, S. K., White, B. M., Kashyap, M. V., Dave, A., De Bie, F. R., Li, H., Singh, K., Menon, P., Wang, T., Teerdhala, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24443-8 · Cited by 67
Aldeeri, A. A., Alazami, A. M., Hijazi, H., Alzahrani, F., & Alkuraya, F. S. (2014) · Clinical Genetics · doi:10.1111/cge.12414 · Cited by 17
Metadata
- Authors
- Muenzer, J.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 111
- Issue
- 2
- Pages
- 63-72
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2115034909
- Cited by
- 182
- References
- 3
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. https://app.cochat.ai/papers/10.1016/j.ymgme.2013.11.015
- The paper
- Muenzer, J. (2014). Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2013.11.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.